[{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Acotiamide","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acotiamide HCl Hydrate","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Swiss Commission for Technology and Innovation | University of Basel | University Hospital, Basel | SocraTec R&D GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Metronidazole Benzoate","moa":"antiprotozoal substances (metronidazole type)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule, Enteric Coated","sponsorNew":"Tillotts Pharma AG \/ Swiss Commission for Technology and Innovation | University of Basel | University Hospital, Basel | SocraTec R&D GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Tillotts Pharma AG \/ Swiss Commission for Technology and Innovation | University of Basel | University Hospital, Basel | SocraTec R&D GmbH"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z-360","moa":"cholecystokinin receptor antagonists","graph1":"Oncology","graph2":"Phase II","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Z-360","moa":"cholecystokinin receptor antagonists","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Tillotts Pharma AG","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tillotts Pharma AG \/ Tillotts Pharma AG","highestDevelopmentStatusID":"11","companyTruncated":"Tillotts Pharma AG \/ Tillotts Pharma AG"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Tillotts Pharma AG","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Tillotts Pharma AG"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Astellas Pharma"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z-100","moa":"Interferon receptor (IFNR)","graph1":"Oncology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Z-100","moa":"Interferon receptor (IFNR)","graph1":"Oncology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Tillotts Pharma AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Zeria Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Zeria Pharmaceutical"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Tillotts Pharma AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Zeria Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Zeria Pharmaceutical"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase II","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Vifor Pharma"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"14-C Z-215","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Z-213","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Z-213","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z-213","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Z-215","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Z-215","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Z-521","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Hans T\u00f6rnblom","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tillotts Pharma AG \/ Hans T\u00f6rnblom","highestDevelopmentStatusID":"8","companyTruncated":"Tillotts Pharma AG \/ Hans T\u00f6rnblom"}]
Find Clinical Drug Pipeline Developments & Deals by Zeria Pharmaceutical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
